Mesoblast Limited · ASX:MSB
Mesoblast — Shareholder Meeting (November 2010)
17 slides from Mesoblast's shareholder meeting presentation, Nov 29, 2010
Slide 1: Building a Solid Future: Address by Chairman Brian Jamieson
For personal use only Building a Solid Future Address by Mesoblast Chairman Brian Jamieson 2010 Annual General Meeting Ladies and gentlemen It is with great pleasure that the Board of Directors of Mesoblast Limited welcomes you to our sixth annual general meeting. It is also my great privilege to re
Slide 2: For personal use only
For personal use only During the 2010 financial year, we created additional value for shareholders by: Executing a strategic and intelligent approach to commercialization Increasing our global presence Recruiting more patients for clinical trials Exploring opportunities for accelerating the
Slide 3: For personal use only
For personal use only I would also like to record our sincere appreciation of Byron McAllister who is stepping down as a Non-executive Director of Mesoblast. For the past six years, Byron has served the Board with distinction and has been particularly invaluable in providing advice on regulatory mat
Slide 4: Leading the world in novel adult stem cell therapies
For personal use only Leading the world in novel adult stem cell therapies Shareholder Annual General Meeting (AGM) November 29th, 2010 Presented by: Silviu Itescu, Executive Director
Slide 5: Mesoblast ownership
Mesoblast ownership For personal use only Share Register Institutions and sophisticated investors 76% Retail 24% RETAIL INVESTORS Investor Location (unclassified) 23% UK 13% NEW ZEALAND AUSTRALIA EUROPE (EX 61% 2% UK) 1% 2
Slide 6: Financials: Capital structure
Financials Capital structure Pre-merger Post-merger For personal use only Issued shares 155m ~230m Current share price $3.16 $3.16 Market cap $490m $727m Options & US Capital raisings IPO (Dec 04) Jul-06 Dec-07 Apr-09 May-10 Total raisings Funds raised (Au$m) 21.0 17.4 13.4 10.8 37.0 18.2 117.8m Pla
Slide 7: The Mesoblast value proposition – a sound technology base
The Mesoblast value proposition – a sound technology base For personal use only 1. The foundation: is our dominant global IP position granted composition patents in major markets, including US backed by use and method applications 2. The key building blocks: proprietary adult stem cells potent
Slide 8: The Mesoblast value proposition – the right business model
The Mesoblast value proposition – the right business model For personal use only 3. The mortar that binds: the right business model platform technology multiple indications mitigate risk, drive revenues specific products for specific markets – maintain superior margins commercial opportuniti
Slide 9: We own the intellectual property on Mesenchymal Precursor Cells (MPC)
We own the intellectual property on Mesenchymal Precursor Cells (MPC) For personal use only Bone marrow + Bone Products for antibody orthopaedic diseases Magnetic beads Cartilage Products for Magnet MPC highly-expandable + eye diseases non-immunogenic Heart muscle Products for cardiac Culture- disea
Slide 10: Our industrial scale manufacturing process
Our industrial scale manufacturing process For personal use only Homogeneous cell population Bone marrow from universal donor BM + stem cell-binding antibody Well-controlled cell expansion Efficient large-scale expansion Magnetic beads Lower costs of cell culture process Batch-to-batch con
Slide 11: Manufacturing strategy is central to maximising value
Manufacturing strategy is central to maximising value For personal use only 1. State-of-the-art manufacturing plant via strategic alliance cost neutral tax effective geographical location best of breed, cutting edge technology 2. Retain control of manufacture for all products product delinea
Slide 12: Optimizing commercialization pathways
Optimizing commercialization pathways For personal use only 1. Taking individual applications to market on our own manageable marketing and distribution requirements 2. Broad-based partnering of platform technology complex distribution, global marketing reach 3. Partnering specific applications
Slide 13: Three-tiered approach to value creation
Three-tiered approach to value creation For personal use only 1. Near-term revenues approved patient-specific products for elite athletes and high-net worth individuals 2. Mid-term value drivers underpinning capital growth “off the shelf” products for major unmet medical needs 3. Long-term susta
Slide 14: "Off-the-shelf" product portfolio driving value creation
“Off-the-shelf” product portfolio driving value creation IND FDA For personal use only clearance approval Lead products Pre-clinical Phase I Phase II Phase III Bone marrow transplantation Congestive heart failure Spinal fusion Knee osteoarthritis Long bone fracture repair Acute myocardial infarction
Slide 15: Orthopaedic markets (United States)
Orthopaedic markets (United States) For personal use only 1. Spinal fusion > 500,000 procedures each year 2. Intervertebral disc repair/regeneration > 4 million patients affected 3. Repair of non-union long bone fractures 5-10% of all long bone fractures fail to unite (non-union) 4. Knee osteo
Slide 16: Non-orthopaedic markets (United States)
Non-orthopaedic markets (United States) 5 . Cardiovascular diseases For personal use only Congestive heart failure (CHF) – 6 million in US alone, > 600,000 new patients annually Acute myocardial infarction (AMI) – 1.2 million new patients annually 6. Bone marrow transplantation, expansion of umb
Slide 17: Value inflexion points – near term
Value inflexion points – near term For personal use only commencement of Phase 3 cord blood expansion trial for FDA approval successful completion of Phase 2 heart failure trial – progression to Phase 3 pivotal trial successful completion of orthopaedic Phase 2 trials moving diabetes and eye